ClinicalTrials.gg
CompletedNCT00683618Updated Mar 21, 2012Results posted

Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia

A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Hypercholesterolemia, sponsored by AstraZeneca. Completed at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-21.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
934
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
18th of 57
934 · median 203
Started
2008
with 1 other
Phase 3
33 of 59
none open now
Registered
28th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 18th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2008, is one of 33 in phase 3, and was the 28th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

This trial is to compare the efficacy, safety and tolerability of Rosuvastatin with Atorvastatin by assessing the change of LDL-C in patients with hypercholesterolemia and history of coronary heart disease (CHD) or risk equivalent, or a 10 year CHD risk of no less than 10%, following 6-week treatment and a possible 6 week extension treatment.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • HMG-CoA
  • LDL-C
  • CHD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treated for or diagnosed hypercholesterolemia or have had a high risk with hypercholesterolemia
  • LDL-C between 3.36mmol/L and 6.5 mmol/L if not treated with statin or between 2.6mmol/L and 4.14 mmol/L
  • Fasting triglyceride less than 4.52mmol/L

Exclusion criteria

Exclusion Criteria:

  • History of statin induced myopathy
  • Unstable or uncontrolled cardiovascular diseases
  • Familial dysbetalipoproteinemia
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
934 participants (actual)

Study arms

  • Experimental
    1

    Rosuvastatin 5mg qd

    Drug: Rosuvastatin

  • Experimental
    2

    Rosuvastatin 10mg qd

    Drug: Rosuvastatin

  • Active comparator
    3

    Atorvastatin 10mg qd

    Drug: Atorvastatin

Interventions

  • Capsule/Tablet, oral, qd, 6 or 12 weeks

    Also known as: Crestor

  • Capsule/Tablet, 10mg, oral, qd, 6 weeks

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.

    Time frame: baseline, 6 weeks

  2. Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.

    Time frame: baseline, 6 weeks

Secondary outcomes

  1. Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  2. Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  3. Percentage Change From Baseline in Triglycerides (TG) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  4. Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  5. Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  6. Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  7. Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  8. Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  9. Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  10. Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6

    Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

    Time frame: baseline, 6 weeks

  11. Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6

    The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)

    Time frame: week 6

  12. 6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6

    The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL); non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL),non-HDL-C goal \< 3.36mmol/L (130mg/dL)

    Time frame: week 6

  13. Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration

    The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)

    Time frame: from week 6 to week 12

07

Results

Posted Mar 12, 2012

Participant flow

In total 934 patients were enrolled to the study, the study was conducted at 13 investigational sites in China. The first patient was enrolled on 27 May 2008, the last patient was completed on 16 Jul 2009.

Randomised Treatment Period
Participant flow — Randomised Treatment Period
MilestoneRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Started145145146
Completed139143140
Not completed626
Withdrew: Withdrawal by subject412
Withdrew: Protocol violation010
Withdrew: Adverse event202
Withdrew: Reason not provided002
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Started36230
Completed33230
Not completed300
Withdrew: Withdrawal by subject100
Withdrew: Adverse event100
Withdrew: Protocol violation100

Outcome measures

PrimaryPercentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a two-sided significance level of 0.025 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg
percent changeRosuvastatin 5mgAtorvastatin 10mg
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg-41.70 ± 2.62-38.67 ± 2.64
PrimaryPercentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.025 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg
Percent changeRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg-46.28 ± 2.62-38.67 ± 2.64
SecondaryPercentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 65.63 ± 2.296.82 ± 2.293.64 ± 2.31
SecondaryPercentage Change From Baseline in Total Cholesterol (TC ) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6-29.62 ± 1.92-33.14 ± 1.91-28.06 ± 1.93
SecondaryPercentage Change From Baseline in Triglycerides (TG) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · Percent change
Percentage Change From Baseline in Triglycerides (TG) at Week 6
Percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Triglycerides (TG) at Week 6-20.09 ± 4.72-22.05 ± 4.69-20.67 ± 4.73
SecondaryPercentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6-38.60 ± 3.57-46.08 ± 3.57-38.50 ± 3.60
SecondaryPercentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6-36.55 ± 2.40-41.21 ± 2.40-34.67 ± 2.41
SecondaryPercentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 63.67 ± 1.994.25 ± 1.981.79 ± 2.00
SecondaryPercentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6-32.95 ± 2.96-38.04 ± 2.96-31.92 ± 2.99
SecondaryPercentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6-44.07 ± 3.17-50.27 ± 3.16-41.04 ± 3.19
SecondaryPercentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6-41.79 ± 11.54-56.63 ± 11.52-48.33 ± 11.64
SecondaryPercentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6

Analyzed with analysis of covariance (ANCOVA) model with factors fitted for treatment, centre, risk factor, lipid concentration at baseline, treatment by centre and treatment by risk factor with a significance level of 0.05 on ITT population.

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · percent change
Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6
percent changeRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6-37.62 ± 3.15-41.87 ± 3.14-35.15 ± 3.16
SecondaryPercentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6

The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)

Time frame:
week 6
Reported as:
Number · percentage of patients
Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6
percentage of patientsRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 661.079.158.3
Secondary6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6

The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL); non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL),non-HDL-C goal \< 3.36mmol/L (130mg/dL)

Time frame:
week 6
Reported as:
Number · percentage of patients
6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6
percentage of patientsRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 666.978.460.4
SecondaryPercentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration

The percentage of patients achieved LDL-C goal is done in ITT population. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guideline (2001) LDL-C goal: Moderately high risk: 2+ risk factors (10-year risk 10%-20%): LDL-C goal \< 3.36mmol/L(130mg/dL), non-HDL-C goal \< 4.14mmol/L (160mg/dL) ; High risk: Coronary Heart Disease (CHD) or CHD risk equivalents (10-year risk \>20%): LDL-C goal\< 2.60mmol/L (100mg/dL), non-HDL-C goal \< 3.36mmol/L (130mg/dL)

Time frame:
from week 6 to week 12
Reported as:
Number · percentage of patients
Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration
percentage of patientsRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration41.247.6—

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 5mg—1/145 (0.7%)5/145 (3.4%)
Rosuvastatin 10mg—0/145 (0%)3/145 (2.1%)
Atorvastatin 10mg—1/146 (0.7%)0/146 (0%)
Most frequent serious events
Most frequent serious events
EventRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Foot FractureInjury, poisoning and procedural complications1/1450/1450/146
Humerus FractureInjury, poisoning and procedural complications0/1450/1451/146
Most frequent other events
Most frequent other events
EventRosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mg
Blood Creatine Phosphokinase IncreasedInvestigations2/1453/1450/146
Alanine AminotransferaseInvestigations2/1450/1450/146
MyalgiaRenal and urinary disorders1/1450/1450/146

Baseline characteristics

Age Continuous
Age Continuous(Years)Rosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mgTotal
Mean60.4 ± 8.5159.7 ± 10.5758.4 ± 9.2959.5 ± 9.51
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mgTotal
Female848577246
Male525462168
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mgTotal
American Indian or Alaska Native0000
Asian136139139414
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Nativ Hawaiian or other Pacific Islander0000
Low density lipoprotein cholesterol (LDL-C level)
Low density lipoprotein cholesterol (LDL-C level)(mmol/L)Rosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mgTotal
Mean4.242 ± 0.67694.131 ± 0.68184.213 ± 0.66174.186 ± 0.6717
triglyceride (TG) level
triglyceride (TG) level(mmol/L)Rosuvastatin 5mgRosuvastatin 10mgAtorvastatin 10mgTotal
Mean1.921 ± 0.78252.042 ± 0.91642.061 ± 0.89711.991 ± 0.8494
08

Study locations

6 sites
  • Research Site
    Wuhan, Hubei, China
  • Research Site
    Changsha, Hunan, China
  • Research Site
    Shenyang, Liaoning, China
  • Research Site
    Beijing, China
  • Research Site
    Shanghai, China
  • Research Site
    Tianjin, China
09

References and documents

Publications

  • Zhao S, Peng D. Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study. Curr Med Res Opin. 2018 Feb;34(2):227-235. doi: 10.1080/03007995.2017.1371584. Epub 2017 Sep 18. PubMed 28836458 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2008
First posted
May 23, 2008
Start
May 2008
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Mar 12, 2012
Last update
Mar 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00683618
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 23, 2008
Start date
May 2008
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Mar 12, 2012
Last update
Mar 21, 2012

Study contacts

Marie Eckerd
study director · AZ Pharmaceuticals - US
Zhao Shuiping
principal investigator · 2nd hospital of Xiangya medical university

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion